Stephen Brady, Tempest Therapeutics CEO

Tem­pest Ther­a­peu­tics’ triple com­bo shows promise in first-line liv­er can­cer, stock jumps

Tem­pest Ther­a­peu­tics said Fri­day morn­ing that its ex­per­i­men­tal liv­er can­cer ther­a­py on top of stan­dard-of-care treat­ments helped shrink tu­mors in more pa­tients com­pared to stan­dard-of-care alone.

In an ear­ly cut of da­ta from a Phase I/II tri­al, 7 of 40 pa­tients (17.5%) with he­pa­to­cel­lu­lar car­ci­no­ma who were treat­ed with Tem­pest’s TPST-1120 on top of Tecen­triq and Avastin as a first op­tion had con­firmed re­spons­es com­pared with 3 of 29 (10.3%) who re­ceived on­ly Tecen­triq and Avastin.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.